- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03488823
Flavonols and Endothelial Injury (Radialis)
May 14, 2018 updated by: Klinik für Kardiologie, Pneumologie und Angiologie
Evaluation of Effects of Flavonols on Endothelial Function and Hyperplasia of Intima After Endothelium Injury During Transradial Catheter.
With increasing age, arterial endothelial cell function is impaired, which is associated with decreased regeneration response and increased intimal hyperplasia after endothelial injury.
Dietary flavanols can reduce endothelial dysfunction acutely and chronically, but the exact mechanism is unknown.
Recent studies suggest that flavanols may affect important endothelial regeneration response processes and possibly mediate long-term positive vascular effects.
The aim of this study is to investigate age-dependent mechanisms of impaired endothelial regeneration and the influence of dietary flavanols on them.
For this purpose, younger and old male patients, who are clinically indicated for elective transradial catheterization, will get periinterventional a test drink , which is rich on flavonols (800 mg flavanols daily), or control drink.
Administration of drinks is randomized and double-blind.
The test drinks should be given one week before the elective catheter examination until 1 week later.
The endothelial regeneration is to be investigated as endothelium-dependent vasodilation non-invasively in the area of the puncture site on the forearm and by means of biomarkers in the blood.
The endothelial function of the Arteria radialis will be measured with Flow Mediated Dilation (FMD) before and 24 h after catheterization.
One month after catheterization patients undergo ultrasound examination of arteria radialis, to include structural vessel wall changes as intimal media thickness.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
NRW
-
Duesseldorf, NRW, Germany, 40225
- Division of Cardiology, Pulmonology and Vascular Medicine, University Hospital Duesseldorf
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- planed catheterization, that has be done via Arteria radialis
Exclusion Criteria:
- acute infection (CRP>0.5 mg/dl)
- malignant diseases
- heart failure (NYHA III-IV)
- renal failure (GFR<60 ml/min)
- profoundly atrial fibrilation
- hypotension (≤100/60 mmHg)
- intolerance of nitroglycerin
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Young with Flavanol
Young patients (< 45 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink with flavanols ( 2x400 mg Flavanols).
|
Patient will get twice daily drink rich on flavanols (400 mg) since one week before catheterization till one week after catheterization.
|
Placebo Comparator: Young without Flavanol
Young patients (< 45 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink without flavanols .
|
Patient will get twice daily drink without flavanols since one week before catheterization till one week after catheterization.
|
Experimental: Old with Flavanol
Old patients (>60 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink with flavanols ( 2x400 mg Flavanols).
|
Patient will get twice daily drink rich on flavanols (400 mg) since one week before catheterization till one week after catheterization.
|
Placebo Comparator: Old without Flavanol
Young patients (>60 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink without flavanols.
|
Patient will get twice daily drink without flavanols since one week before catheterization till one week after catheterization.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increase of Endothelial Function of Arteria radialis
Time Frame: week 2
|
Change from Baseline Endothelial Function of Arteria radialis measured with Flow Mediated Dilation (FMD) after catheterization
|
week 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Degree of intimal Injury after Catheterization
Time Frame: 1 month
|
Intimal Injury will be measured as intima media thickness with duplex sonography 1 month after catheterization
|
1 month
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Microvascular Function
Time Frame: 1 month
|
Microvascular Function of Endothelium will be measured with Laser-Doppler Examination 1 month after catheterization
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Roberto Sansone, MD, Division of Cardiology, Pulmonology and Vascular Medicine, University Hospital Dusseldorf
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2017
Primary Completion (Actual)
April 30, 2018
Study Completion (Actual)
April 30, 2018
Study Registration Dates
First Submitted
February 15, 2018
First Submitted That Met QC Criteria
April 4, 2018
First Posted (Actual)
April 5, 2018
Study Record Updates
Last Update Posted (Actual)
May 15, 2018
Last Update Submitted That Met QC Criteria
May 14, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 12-012
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endothelial Dysfunction
-
M.D. Anderson Cancer CenterRecruitingEndothelial Dysfunction | Vascular | Endothelial | EndothelixUnited States
-
Clinica ARS MedicaUnknown
-
University of California, San DiegoCompletedEndothelial Dysfunction
-
M.D. Anderson Cancer CenterCompletedEndothelial DysfunctionUnited States
-
NestléCompleted
-
Société des Produits Nestlé (SPN)Completed
-
General Hospital of Chinese Armed Police ForcesChinese PLA General HospitalUnknown
-
University of ConnecticutCompletedEndothelial DysfunctionUnited States
-
Florida State UniversityRecruitingEndothelial DysfunctionUnited States
-
Poznan University of Physical EducationCompletedEndothelial DysfunctionPoland
Clinical Trials on with Flavanol
-
University of ReadingCompleted
-
Heinrich-Heine University, DuesseldorfCompletedCardiovascular DiseasesGermany
-
University of California, DavisMars, Inc.Completed
-
University of NottinghamMars, Inc.CompletedDiabetesUnited Kingdom
-
Heinrich-Heine University, DuesseldorfUniversity of ReadingCompleted
-
Heinrich-Heine University, DuesseldorfCompleted
-
Laval UniversityCompleted
-
Seoul National University HospitalCompleted
-
University of ZurichCompletedStable Coronary Heart DiseaseSwitzerland